Matches in Nanopublications for { ?s ?p "[Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_assertion description "[Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_provenance.
- assertion description "[Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.